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Ciliary neurotrophic factor (CNTF) promotes survival and enhances long-distance regeneration of injured axons in parts of the
adult CNS. Here we tested whether CNTF gene therapy targeting corticospinal neurons (CSN) in motor-related regions of the
cerebral cortex promotes plasticity and regrowth of axons projecting into the female adult F344 rat spinal cord after moderate
thoracic (T10) contusion injury (SCI). Cortical neurons were transduced with a bicistronic adeno-associated viral vector (AAV1)
expressing a secretory form of CNTF coupled to mCHERRY (AAV-CNTFmCherry) or with control AAV only (AAV-GFP) two
weeks prior to SCI. In some animals, viable or nonviable F344 rat mesenchymal precursor cells (rMPCs) were injected into the
lesion site two weeks after SCI to modulate the inhibitory environment. Treatment with AAV-CNTFmCherry, as well as with
AAV-CNTFmCherry combined with rMPCs, yielded functional improvements over AAV-GFP alone, as assessed by open-ﬁeld
and Ladderwalk analyses. Cyst size was signiﬁcantly reduced in the AAV-CNTFmCherry plus viable rMPC treatment group.
Cortical injections of biotinylated dextran amine (BDA) revealed more BDA-stained axons rostral and alongside cysts in the
AAV-CNTFmCherry versus AAV-GFP groups. After AAV-CNTFmCherry treatments, many sprouting mCherry-immunopositive
axons were seen rostral to the SCI, and axons were also occasionally found caudal to the injury site. These data suggest that
CNTF has the potential to enhance corticospinal repair by transducing parent CNS populations.
1. Introduction
Most spinal cord injury (SCI) results from contusion rather
than transection injuries, and cervical injuries (~60–70% of
all SCI) produce greater deﬁcits and threaten more critical
survival systems than thoracic/lumbar SCI. The corticospinal
tract (CST) is important in the control of voluntary skilled
movements, especially of distal limbs. Human CST projec-
tions are not completely homologous to the descending
CST in rodents (which in these species projects mainly to
the forelimbs and is mainly located in the dorsal rather than
lateral columns) [1], nonetheless, because of the importance
of CST projections in ﬁne manipulatory motor control, this
pathway has been a focus of many experimental repair strat-
egies aimed at restoring function following SCI. Most studies
in rodents have attempted this by the delivery of puriﬁed neu-
rotrophic growth factors and/or by cell transplantation using
donor cells engineered to overexpress the growth factors, the
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factors usually applied to the injury site itself (see [2]). In such
studies, functional improvements usually reﬂect sprouting
and some plasticity in collateral and/or intraspinal pathways
([3, 4], c.f. [5]), rather than axonal regeneration per se.
Our gene therapy approach targets corticospinal neurons
(CSN) and is aimed at enhancing axonal plasticity and induc-
ing regeneration of CST axons, leading to behavioural
improvements after SCI. Gene therapy involves the transduc-
tion of neurons in the sensorimotor cortex using a bicistronic
adeno-associated viral vector (AAV) that encodes and
expresses a secretory form of ciliary neurotrophic factor
(CNTF) coupled to mCHERRY (AAV-CNTFmCherry). Injec-
tion of AAV-CNTFmCherry into the cortical regions of the
brain that project onto the output pathways of the CST
allows expression of CNTF in neurons, including CSN, at
the time of SCI.
CNTF has been selected because it is known to promote
the survival of injured CSN [6], and in other systems it pro-
motes long-distance regeneration of injured adult CNS axons
[7–10], with at least some functional outcomes [11]. CNTF is
a neuropoietic member of the interleukin 6 (IL-6) cytokine
family, expressed primarily in glial cells of the nervous sys-
tem [12–15]. Survival eﬀects of CNTF have been demon-
strated on motor, retinal ganglion, cortical and hippocampal,
red nucleus, and striatal and thalamic neuron populations
[14–16] (see also [17]). CNTF has demonstrated eﬃcacy in
limiting neuronal injury in several experimental disease and
injury paradigms, and has been clinically evaluated as a treat-
ment for motor neuron-speciﬁc amyotrophic lateral sclerosis
(ALS) [18, 19]. CNTF protects corticospinal neurons in the
sensorimotor cortex after intracortical axotomy [6], and these
neurons, at least in murine neonates, are known to express
CNTF receptor α [20]. Functional improvement and
enhanced remyelination has also been reported after intrasp-
inal transplantation of oligodendrocyte precursor cells
expressing CNTF [21]. However, as we have argued [2], while
most SCI studies have targeted the injured cord itself for ther-
apy, in other systems—such as the visual system—targeting
the injured neurons themselves yields excellent functional
outcomes [11, 22]. Most importantly there is now clear evi-
dence in human postmortem material that there is long-term
survival of CSN after SCI [23], making strategies that target
these neurons of genuine clinical relevance, potentially in both
acute and chronic circumstances.
In an initial study, we obtained preliminary evidence that
AAV2.1-CNTFmCherry transduced large numbers of neurons
in the sensorimotor cortex containing CSNs projecting into
the spinal cord, and after moderate thoracic T10 contusion
SCI there was clear and consistent sprouting of mCherry-
labelled CST axons at, and rostral to, the lesion site [2]. In
the present report, cortical gene therapy has been also com-
binedwith the transplantationofmesenchymal precursor cells
(MPCs) into the injured thoracic cord, a method shown by us
and others consistently to limit tissue loss and promote
morphological sparing as well as functional improvement
following SCI [24, 25]. The rationale is that a healthier
local environment at the cell-transplant injury site provides
a better terrain for plasticity and regeneration of CST axons
after targeted CNTF expression in the motor cortex. MPC
treatment may be especially needed for contusion injuries
which tend to be more unstable and prone to cyst
formation—this is vital when treating cervical injuries in
humans due to ongoing cavity formation (syringomyelia)
and consequent progressive, sometimes catastrophic, loss of
function [26].
2. Materials and Methods
2.1. Animals and Experimental Design. Adult female Fischer
(F344) rats (age 10–12wk, 120–150 g; Animal Resource Cen-
tre, Western Australia) were used in experimental proce-
dures conforming to National Health and Medical Research
Council Guidelines (Australia) and approved by the Univer-
sity of Western Australia Animal Ethics Committee. A total
of 43 rats was used, distributed between 4 experimental
SCI groups as follows; SCI+ control AAV-GFP (n = 11),
SCI+AAV-CNTFmCherry (n = 16), SCI+AAV-CNTFmCherry +
nonviable rMPCs (n = 6), and SCI+AAV-CNTFmCherry +
viable rMPCs (n = 11). Previous experiments conducted in
our lab used SCI + either nonviable or viable rMPC cell trans-
plantation only [24, 25], and to satisfy NHMRC guidelines to
address animal welfare and minimise animal use, these
groups were not repeated for the present study. Viral AAV
transduction was performed 2 weeks prior to SCI, and
2 weeks prior to experimental endpoint, biotinylated
dextran amine BDA conjugated to horseradish peroxidase
(Thermo Fisher Scientiﬁc) was spaced and injected in vir-
tually identical positions as the earlier AAV injections in
order to cover the same hindlimb projection ﬁelds in the
sensorimotor cortex. Endpoint was reached and animals
culled at day 56 after SCI.
2.1.1. Viral Vectors. The bicistronic adeno-associated viral
vector (AAV) encoding and expressing a secretory form of
CNTF coupled to mCHERRY (AAV-CNTFmCherry) or
vector-alone control linked to green ﬂuorescent protein
(AAV-GFP) were made by Vector Biolabs, USA. AAV
vectors consisted of an AAV2 DNA backbone in an AAV1
capsid. This particular serotype has been shown to provide
excellent transduction of cortical neurons [27–29]. Trans-
gene expression was driven by a shortened CAG2 promoter
based on the typical cytomegalovirus/chicken beta-actin
(CAG) promoter. For bicistronic vectors, the transgene
(CNTF) and reporter (mCherry) were linked by a 2A viral
peptide sequence, which causes a “translational skip” and
results in a 1 : 1 expression of transgene and reporter pro-
teins. The CNTF transgene is a mouse CNTF gene preceded
by the secretory signal sequence from mouse pre-pro-NGF,
to allow for local secretion of CNTF [30] (a gift from Prof.
M. Sendtner, University of Wurzburg, Germany).
2.1.2. Viral Transduction of Hindlimb Sensorimotor Cortex.
AAV-CNTFmCherry or AAV-GFP transduction of CSN in
the cortical regions that project axons to the level of the spi-
nal cord that controls the hindlimbs [2, 31] was performed 2
weeks prior to SCI via 4× 0.5μl injections of the respective
virus (~4× 1013 genomic copies/ml) using a nanojet device
and a digital stereotaxic frame (Kopf) for accurate Bregma/
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Lambda coordinate positioning. Injection of AAV 2 weeks
prior to SCI allowed time for onset of transgene expression
and production of CNTF.
2.2. Spinal Cord Injury (SCI). Rats were anesthetized with
1.5% (v/v) halothane (Rhone-Poulenc Chemicals Pty. Ltd.,
Australia) combined with nitrous oxide (60%) and oxygen
(38.5%). Amacin ophthalmic eye ointment was applied before
rats were placed on a heating pad (37°C). Partial laminectomy
at vertebral level T9-T10 exposed the SC underneath without
disrupting the dura [24, 25]. Using an Inﬁnite Horizon
impactor device, a 200 kDyne contusion injury was induced
at the exposed spinal cord. Postsurgery care, analgesics, food,
and housing were as previously described [24, 25]. Brieﬂy,
rats were treated with Benacillin (0.02ml/100 g body wt.,
300U/ml, i.m.) and painkiller Buprenorphine (Temgesic,
0.01ml/100 g, 300U/ml, ip) for 5 days.
2.3. Donor rMPCs and Transplantation. Commercially
available rMPCs isolated from Fischer F344 rats (Cyagen
Biosciences Inc., number RAFMX-01201) were routinely
maintained in Mesenchymal Stem Cell Growth Medium
(number GUXMX-90011) prior to use in transplantation
experiments, or for those used for routine phenotypic charac-
terization and diﬀerentiation [24, 25] maintained for at least
24–48 hr, in order to determine any neuronal phenotype/
marker expression using the panel of antibodies described
in Section 2.7.2. For transplantation experiments, MPCs
(no higher than passage number 5) were washed and
resuspended in PBS. Nonviable MPCs were prepared by
multiple (×3) freeze/thawing steps between −80°C and 37°C
and conﬁrming loss of viability using trypan blue staining
under microscopy. At day 14 after SCI, 6× 105 cells in a
total of 4μl were injected in a single injection directly into
the lesion site (rostrocaudally at 1mm depth) through a
ﬁnely drawn (80μm tip) glass pipette connected to a
10μl Hamilton syringe and driven by a Harvard Pump
at 0.5μl/min (total duration is 8min). The pipette was
left in place to prevent cell leakage for 1min before
withdrawal [24, 25].
2.4. BDA Injection into Sensorimotor Cortex that Projects to
Low Thoracic/Lumbar Spinal Cord. Injections of biotinylated
dextran amine were spaced in virtually identical positions as
the earlier AAV-CNTFmCherry or AAV-GFP transduction
injections in order to cover the same hindlimb projection
ﬁelds in the sensorimotor cortex. For each of the 4 injec-
tions, 0.5–1μl of 10% (w/v) BDA were injected using a
nanojet device (World Precision Instruments) at a depth
of 1mm. The location of these injections is based on studies
showing the location of CMN that project to the hindlimbs
and forelimbs in Fischer rats [2] and conﬁrmed by the
examination of the label in appropriate thalamic motor
nuclei. In some rats, gelfoam soaked in the BDA solution
was placed over the exposed cortex prior to the closure of
the craniotomy.
2.5. Functional Behaviour. A variety of behavioural tests for
injured rats were used to give a valid indication of functional
recovery [24, 25, 32–35] including (i) “open-ﬁeld” locomotion
test (BBB scoring method [36] to assess spontaneous move-
ments), (ii) ladder walking [37] to assess general hindlimb
recovery, and (iii) our own novel computerized quantitative
gait analysis method (Ratwalk® [38]) which allows objective
analyses of a large number of locomotion parameters, such
as interlimb coordination (step sequence), stride length, step
length, and base of support (stance width) [38]. All functional
(locomotor) behaviour was assessed weekly for up to day 56
after SCI. BBB scoring was analysed using at least 3 blinded
raters both at the time of assessment and later in silica via slow
motion/frame-by-frame replay of high deﬁnition (1080 p)
digital recordings taken during the test. The BBB rating score
is composed of 22 nonlinear operational deﬁnitions (0–21
scale) studying several aspects involved in the locomotion of
quadrupedal animals such as weight support, plantar step-
ping, and forelimb/hindlimb coordination. Ladderwalk and
Ratwalk assays were performed on animals once they had
reached weight support on their hindlimbs, and involved
comparison of preinjury performance with weekly assess-
ments from day 14 post-SCI until day 56 (endpoint). Digital
recordings of animals traversing 3 lengths per time point of
Ladderwalk and Ratwalk (preinjury and weekly up to day 56
post-SCI) were also similarly assessed by at least 2 blinded
raters in silica via slow motion/frame-by-frame replay of dig-
ital recordings taken during the tests for preinjury and up to
day 56 post-SCI. Ladderwalk scores are an average ofmissteps
over a 1m horizontal ladder with unevenly spaced bars.
Ratwalk data analysis involves frame by frame designation
from digital recordings of left and right fore- and hindlimb
placement on a 1m glass platform in the Ratwalk apparatus
in low light, using an average of 3 “runs” per time point [38].
2.6. Perfusion and Tissue Processing. At day 56 (2 weeks after
the BDA cortex injections), rats were euthanized by lethal
injection of sodium pentobarbitone (50mg/100 g) and trans-
cardially perfused in 0.9M with 100ml of heparinized Dul-
becco’s PBS followed by 4% (w/v) paraformaldehyde in PBS
pH7.4. The head and vertebral column were dissected from
each animal and postﬁxed for 24 hours. The brain and spinal
cord were extracted from the skull and vertebra and then
stored intact in 0.1M PBS (pH7.4). The position of the injury
in the SC was measured from the caudal edge of the cerebel-
lum to conﬁrm that all animals were lesioned at the same
level. A 2 cm segment was cut from the SC, with the lesion
at the midpoint of this segment, and embedded in 1% (w/v)
gelatin (Sigma-Aldrich). Using a CO2-freezing microtome
(Polycut, Reichert-Jung, Australia), proximal and distal SC
close to the grafts (1 cm) was cut sagitally in 40μm frozen
sections, while the brain and brainstem were cut transversely
in 50μm frozen sections. A consecutive series of sections
were transferred to 24-well plates containing 0.1M PB with
0.01% (w/v) sodium azide (Sigma-Aldrich) and stored at
4°C until processed for immunohistochemistry.
2.7. Tissue Analysis
2.7.1. Axonal Transduction and Anterograde Tracing. Frozen
coronal brain sections were examined for preinjury AAV-
CNTFmCherry or AAV-GFP transduction in the cortex and
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Figure 1: (a) Two AAV-CNTFmCherry injections in the cerebral cortex. (b) BDA injections into the cortex revealed using immunoperoxidase;
note the many labelled neurons in deeper layers. This animal had previously received cortical injections of AAV-CNTFmCherry. (c–l)
Longitudinal sections of the spinal cord—in all cases rostral is to the left of the picture. (c) Section immunostained for mCherry (red)
and β-III tubulin (green) showing anterogradely labelled mCherry-positive axons (arrow) in the dorsal corticospinal tract far rostral
to the lesion site. (d) Control AAV-GFP-injected rat (no MPCs injected); a small number of immunoperoxidase BDA-labelled axons and
debris are visible just in front of a rostral cyst (arrow), with no axons extending beyond the injury. (e–g) Large numbers of mCherry-positive
axons rostral (e, f) and running dorsally over and beyond the cyst (g); these rats received AAV-CNTFmCherry cortical injections plus an
intraspinal injection of viable rat mesenchymal precursor cells (rMPCs). Note in (e) the profusion of mCherry-positive proﬁles (large arrow)
approximately 1mm rostral to the lesion cavity, growing into regions dorsal to the corticospinal tract (small arrows). There appears to be
considerable sprouting of axons in this zone (f). (h) Immunoperoxidase BDA-labelled axons and debris rostral to a cyst in a rat injected with
AAV-CNTFmCherry. Several axons can be seen running caudally, ventral to the cyst (arrows). (i) BDA-labelled cortical axons (arrows)
visualized using a ﬂuorescent secondary antibody (green), running over a cystic cavity. This animal also received AAV-CNTFmCherry and
viable MPC injections. (j–l) Cortical axons (arrows) double labelled (l) with both mCherry ((j), red) and BDA ((k), green); note, some axons
are only mCherry or BDA immunoreactive. Scale bars: (a, e), 500μm; (b, h, and i), 200μm; (c, d, g, and j–l), 100μm; and (f) 50μm.
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thalamus using immunoﬂuorescence, in addition to post-
SCI anterograde BDA labelling using both immunoﬂuores-
cence and immunostaining with horseradish peroxidase
(HRP). At the lesion site, longitudinal SC sections were
similarly examined for axonal sprouting and regrowth
(BDA). After blocking for 30min in PBS containing 10%
(v/v) normal goat serum and 0.02% (v/v) Triton X-100,
AAV-transduced axons were immunolabelled overnight
at 4°C using antibodies to mCherry (Living Colours,
1/600 in PBS). After washes, a secondary Cy3 goat anti-
mouse antibody (Jackson ImmunoResearch 115613, 1/500
dilution in PBS) was applied for 30min at room tempera-
ture, before unbound antibody was washed away and
sections coverslipped. In most cases, BDA was visualized
using commercial VECTASTAIN avidin-biotin (Vector
Laboratories, USA, number PK-4000) kits (as per
manufacturer’s instructions) and horseradish peroxidase
(HRP) histochemistry. Brieﬂy, avidin-biotinylated (ABC)/
HRP, followed by 3,3′-diaminobenzidine (DAB) solution
was used to visualize BDA-stained axons. The ABC/HRP
reagents were prepared 30 minutes before application to the
sections. The sections were incubated with ABC reagents for
1.5 hours at room temperature and washed with PBS. A
DAB solution (10% (v/v) DAB metal concentrate in peroxi-
dase buﬀer) was then added to the sections and incubated for
5–15 minutes on a shaker. Sections were washed with PBS,
allowed to air dry overnight and then counterstained with
1% (w/v) toluidine blue and coverslipped with DEPEX
mountingmedium (Fronine Lab Supply, Australia). To enable
identiﬁcation of bothmCherry and BDA-labelled axons in the
same longitudinal tissue sections, BDAwas occasionally visu-
alized using FITC-conjugated anti-streptavidin secondary
antibodies (Thermo Fisher Scientiﬁc). In AAV-GFP-injected
rats, brain and spinal cord sections were immunostained
with an antibody to GFP (rabbit 1/500, Millipore, in
PBS) followed by goat anti-rabbit IgG FITC-conjugated
secondary antibodies (Jackson ImmunoResearch 89751,
diluted 1/100 in PBS) similarly described as above.
In mCherry-, GFP-, and BDA-stained sections, the
accumulation of debris and branching of CST axons were
commonly seen rostral to the SCI and associated cysts.
Axon sprouting was especially evident in AAV-CNTF-
injected animals. In a series of sagittal sections, the rostral
extent of this region was measured from the beginning of the
injury site in 38 rats (n = 6 for AAV-GFP; n = 15 for AAV-
CNTFmCherry; n = 6 for AAV-CNTFmCherry +nonviable
rMPCs; and n = 11 for AAV-CNTFmCherry + viable rMPCs).
2.7.2. Immunohistochemical Analyses of Glial and Neuronal
Phenotypes. Brain and spinal cord tissue sections were
blocked in 10% (v/v) fetal calf serum (Gibco, BRL) and
0.2% (v/v) Triton X-100 in PBS for 10 minutes at room
temperature and washed in PBS. Primary antibodies (diluted
at 1/500 in PBS unless otherwise stated) to conﬁrm the
expression of phenotypic markers for glial cells, GFAP in
spinal cord (Millipore, AB3080), and axon populations using
antibodies to β-III tubulin (Covance, PRB-435) in the brain
and spinal cord were used. Detection using FITC- or Cy3-
conjugated secondary goat anti-mouse or goat anti-rabbit
antibodies (diluted at 1/400 in PBS, Jackson ImmunoRe-
search, 115613, 89751) as described previously [24, 25].
2.7.3. Quantitative Analysis of Tissue Sparing in the Spinal
Cord. At least two independent raters (blinded) also mea-
sured cyst sizes to remove bias. Tissue sparing was assessed
by measuring cyst size and the amount of intact versus
degenerating tissue [24, 25]. Brieﬂy, assessment of spinal
tissue sparing was carried out using 0.05% (w/v) toluidine
and 0.005% (w/v) borax solution followed by dehydration
in sequentially graded ethanol (v/v) of 70%, 90%, and
100%. Staining on every sixth sagittal section was used to
determine the volume of spared spinal tissue. In each section,
the total number of pixels in a 2.5mm-long SC segment was
determined, with the lesion epicenter in the middle, as well as
the area of damaged spinal tissue around it. The border of the
damaged tissue was deﬁned by the absence of healthy cells
and an obvious discontinuity in density. Measurements of
each section were summed per rat and averaged to give the
amount of spared tissue, and percentage was calculated as
the diﬀerence between the area of damaged tissue versus
the whole segment (ﬁeld of view) [24, 25].
2.7.4. Microscopy. A Nikon Eclipse E800 microscope was
used to visualise immunoﬂuorescence staining as well as con-
ﬁrm successful BDA injection into the brain and to visualize
BDA-stained axons at the SCI site. The distances between the
front edge of the most rostral cyst (if there was more than
one) and any axons observed alongside or caudal to the cyst
were measured using the NIS elements BR 4.5 software.
2.7.5. Statistics. Using GraphPad Prism v4.03, SBSS (version
21.0) and InStat v3.06 for Windows (GraphPad Software,
San Diego, USA), 1- and 2-way repeated measures using
either one- or two-way analysis of variance (ANOVA) plus
Tukey’s post hoc analysis as required were performed,
except for BBB scoring which uses Kruskal-Wallis analysis
(nonparametric ANOVA) as described previously [24, 25].
In addition, Mann–Whitney post hoc testing was performed.
3. Results
3.1. Preinjury AAV Gene Therapy and Postinjury BDA
Injection into the Cortex. Both GFP and mCherry expression
in transduced axons following AAV-GFP control and bicis-
tronic AAV-CNTFmCherry injections into the cortex prior to
SCI were conﬁrmed at day 56 post-SCI using immunoﬂuores-
cence microscopy on relevant brain sections (Figure 1(a)).
Note that the mCherry expression in neurons was conﬁrmed
through all the layers of cortex, including layer V containing
CSN; this robust, post-2A linker expression is indicative of
widespread transduction and expression of the secretable
form of CNTF. BDA injection sites in the cortex were
also visualized with ABC/HRP and DAB reaction (see
Figure 1(b)) or immunoﬂuorescence at day 56. BDA
staining reached layer V of the cortex indicating the success-
ful labelling of CSN and, as for mCherry expression, the label
in the ventrolateral nucleus of the thalamus conﬁrmed
injection into appropriate sensorimotor cortical regions.
The appearance of BDA in the same tracts in the cortex as
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transduced AAV-GFP control and AAV-CNTFmCherry
conﬁrms that we were able to successfully label similar areas
of axonal projection from the cortex that would facilitate
identiﬁcation within the CST regions of the spinal cord.
3.2. AAV-Transduced and BDA-Labelled Projections in the
Spinal Cord. In all treatment groups, AAV-transduced,
immunostained axons and BDA-immunolabelled axons were
seen in the contralateral CST rostral to the injury site. An
example is shown in Figure 1(c) with AAV-CNTFmCherry-
labelled axons (red) in the CST adjacent to βIII tubulin-
positiveﬁbers andneurons (green).While nearly allCSTﬁbers
were well aligned in the ventral dorsal column in segments far
rostral to the SCI site (Figure 1(c)), immediately in front of the
injury these axons became disorganized and more broadly
distributed. In this region, in addition to degenerate axon pro-
ﬁles and other debris, apparently intact CST axons possessed
complex, irregular proﬁles strongly suggestive of local sprout-
ing and regenerative responses. In AAV-GFP control rats,
there were small numbers of these axons immediately rostral
to the ﬁrst lesion cavity; however, in this group GFP-positive
or BDA-labelled CST axons were never seen caudal to the
injury/cyst. Furthermore, compared to animals injected with
AAV-CNTFmCherry (Figures 1(e)–1(g)), there was greater
axon dieback as well as relatively little sprouting. The best
example is shown in Figure 1(f) (BDA label). By comparison,
in rats with AAV-CNTFmCherry cortical injections, there
was consistently a much higher density of CST axons
400–1000μm rostral to the ﬁrst spinal cord cavity, as revealed
in bothmCherry- (Figures 1(e)–1(g)) and BDA- (Figure 1(h))
immunostained material.
In a series of mCherry- or BDA-immunostained sagittal
sections, the rostral extent of the zone containing scattered,
often branched, CST axons was measured from the begin-
ning of the injury site (taken as the rostral edge of the ﬁrst
lesion cavity) in 38 rats. These “expanded” zones of CST
label (Figures 1(e)–1(h)) were seen in 3/6 AAV-GFP-
injected rats, 9/15 AAV-CNTFmCherry rats, 4/6 rats with
AAV-CNTFmCherry + nonviable rMPCs, and 8/11 rats with
AAV-CNTFmCherry + viable rMPCs. The mean rostral extent
of this zone was 323± 125μm (S.D.), 483± 226μm, 475
± 330μm, and 638± 370μm for the four groups, respectively.
There was considerable interanimal variability as shown by
the large standard deviations, nonetheless the trend for
increased density and greater areal extent of rostral CST
sprouting in AAV-CNTF-injected animals is evident.
After AAV-CNTF but not AAV-GFP cortical injections,
many labelled CST axons were located beyond the rostral
edge of the cyst (Figure 1(g)). Growth of BDA-positive axons
beyond the cyst was also seen (arrows, Figure 1(h)). Long-
distance growth of axons was also occasionally seen as shown
in Figure 1(j); again, note the irregular nature of the postin-
jury BDAFITC-labelled axonal proﬁles. This animal also
received a viable MHC graft. In sections immunostained for
both mCherry (red) and BDA (FITC—green), we observed
occasional axons that were both AAV-CNTFmCherry- and
anti-BDAFITC-positive (arrows, Figures 1(j)–1(l)). In the
example shown, the axons were located ventral to a cyst.
The double labelling indicates that at last some of the
mCherry and BDA cortical injections were successfully made
in overlapping regions of cortex, resulting in the dual label of
the projecting layer V pyramidal neurons.
Figure 2 shows representative longitudinal spinal
cord sections from three animals treated either with
AAV-CNTFmCherry alone (Figures 2(A)–2(H)) or AAV-
CNTFmCherry + viable rMPC transplantation (Figures 2(I),
and 2(J)). Low power images show the size and location of
cysts in two of these animals (Figures 2(A) and 2(F), resp.).
The arrows in Figures 2(A) and 2(F) point to the approxi-
mate postcyst location of the mCherry-positive axons
shown in Figures 2(D), 2(E), and 2(I). In the rat shown in
Figures 2(A)–2(E), there were large numbers of mCherry-
positive ﬁbers dorsal to the ﬁrst large cyst in regions of spared
tissue midway within the lesion site (arrow, Figure 2(B),
shown in higher power in Figure 2(C). More importantly,
we also observed AAV-CNTFmCherry-positive ﬁbers in the spi-
nal cord distal to the lesion (Figures 2(D) and 2(E)). These
ﬁbers were nonlinear in orientation and, although infrequent,
they were located up to 3-4mm beyond the rostral edge of the
injury site. In the animal shown in Figures 2(F)–2(H), again
there were many mCherry-immunopositive axons located just
in front of, and dorsal to, the rostral cavity (Figure 2(G)), and
many sprouting BDA-positive axons were also seen. However,
in this animal, there were only a small number of mCherry-
labelled axons located caudal to the injury site (arrows,
Figure 2(H)). It is worth emphasizing in Figures 2(D), 2(E),
and 2(I) that the irregular course and branching of these axons
are strongly suggestive of regenerative growth. One other rat,
this one treated with both AAV-CNTFmCherry and viable
rMPCs, possessed a number of mCherry-labelled axons distal
to the contusion injury and to the most caudal lesion cavity
(arrows, Figures 2(I) and 2(J)).
3.3. Functional Hindlimb Recovery Is Generally Enhanced
after CNTF Gene Therapy
3.3.1. Ladderwalk. The number of missteps over the
Ladderwalk apparatus showed a gradual decline for all
treatment groups from day 14 through to endpoint at
day 56 after SCI (Figure 3). Animals treated with control
AAV-GFP after SCI had the highest misstep counts across
all time points, with the average decreasing gradually from
12 at day14, to 8 at day 56, respectively. Rats with SCI
followed by AAV-CNTFmCherry treatment consistently
displayed a lower average number of missteps than control
AAV-GFP treatment, decreasing gradually from ~9 at
day14 to ~6 at day 56, respectively. The combined AAV-
CNTFmCherry treatment with either nonviable or viable
rMPC transplantation at the lesion site markedly reduced
the average numbers of missteps, ranging from 3 to 6 at
day 14 after SCI, with both of these groups showing very
similar average missteps of 3 from day 28 until day 56
after SCI. Two-way ANOVA showed statistically signiﬁ-
cant diﬀerences (pairwise comparisons) between all
groups from day 14 until day 56 after SCI (p = 0 002,
0.003, 0.006, 0.001, 0.013, 0.002, and 0.032 at days 14, 21, 28,
35, 42, 49, and 56, resp.). Post hoc tests revealed statistically
signiﬁcant diﬀerences between the AAV-GFP-treated control
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group and AAV-CNTFmCherry +nonviable rMPCs at all time
points as well as between theAAV-GFP-treated control group
and AAV-CNTFmCherry + viable rMPCs at all time points
except day 14 and day 56 (Figure 3).
Because the two-way ANOVA with repeated mea-
sures described above showed a signiﬁcant interaction
(p = 0 0001), we then separated the factors and performed a
one-way ANOVA on all AAV-CNTFmCherry-treated animals
Figure 2: Two examples (A–E and F–H) of animals that received cortical AAV-CNTFmCherry injections and with mCherry-positive
corticospinal axons distal to spinal cysts (D, E, I and J), and therefore distal to the initial injury. In all images rostral is to the left. (A, F)
Low power views of cysts (β-III tubulin-immunostained sections) in each rat; the arrows in (A) and (B) point to the approximate location
of the axons shown in (D, E, and H), respectively. (B, C) Large numbers of mCherry-positive axons (arrow) dorsal to the large rostral cyst
(see (A)), with small numbers of irregularly organized axons distal (D, E). (G) mCherry-labelled axons rostral and dorsal to the cyst, with
several axons (arrows) located distal to the injury (H). In one animal injected with AAV-CNTFmCherry and that received a spinal rMPC
injection, numerous mCherry-positive axons (arrowed) were seen distal to the most caudal lesion cavity (I, J). Scale bars: (A, F), 1mm;
(B), 500 μm; (C, G), 200 μm; (D, E, I, and J), 100μm; and (H) = 50μm.
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at day 14 only. This one-way ANOVA revealed that there was
no diﬀerence between the cell-type (no cell, viable, and nonvi-
able rMPC) treatments for the AAV-CNTFmCherry-treated
cohort at day 14 (p = 0 395), to be expected given that the
Ladderwalk tests were performed prior to rMPC
transplantation at this time point. Note that the number of
animals per group at day 14was less than at later times because
only those animals that supported their weight on their
hindlimbs could be tested. Additionally, the one-way repeated
measures ANOVA within the AAV-CNTFmCherry animals
revealed that while there was an overall eﬀect of a reduction
in missteps over time (p = 0 001), there was no diﬀerence
between the cell-type treatment groups (p = 0 143). Interest-
ingly however, in the AAV-CNTFmCherry-injected rats only
the AAV-CNTFmCherry without rMPC group showed a
signiﬁcant reduction in missteps (p = 0 05, LSD test) across
time with post hoc testing.
3.3.2. Open-Field Locomotion (BBB). BBB scores for hindlimb
recovery (Figure 4) revealed signiﬁcant diﬀerences between
the AAV-GFP-treated control group (green) compared to
the AAV-CNTFmCherry (red, crosses), AAV-CNTFmCherry +
nonviable rMPC (black), and AAV-CNTFmCherry + viable
rMPC (blue) treatment groups, generally from day 21
onwards. All treatment groups followed a slow increase in
average BBB scores (0-1 at day 0 following SCI) until around
day 5–day 7 when average scores began to typically increase
at a greater rate, with the AAV-GFP-treated control group
consistently showing the lowest average BBB scores of 5 from
day 7 (which corresponds to a slight movement of two joints
and an extensive movement of the third joint) until score
10 at day 56 after SCI (which corresponds to plantar
stepping with occasional weight bearing and no forelimb-
hindlimb coordination). AAV-CNTFmCherry and AAV-
CNTFmCherry + nonviable rMPC groups’ scores plateaued
from day 21 after SCI with an average BBB score of 11 (which
corresponds to plantar stepping with frequent to consistent
weight bearing and NO forelimb-hindlimb coordination).
Only the AAV-CNTFmCherry and AAV-CNTFmCherry + viable
rMPC treatment group obtained higher scores from day 42
until day 56 after SCI, where average BBB scores plateaued
at 12 (which corresponds to plantar stepping with frequent
to consistent weight bearing and occasional forelimb-
hindlimb coordination), suggesting that CNTF gene therapy
alone and CNTF gene therapy+ viable MPC transplantation
into the lesion resulted in the best functional outcomes.
Kruskal Wallis scores showed overall statistically signiﬁcant
diﬀerences between the AAV-GFP-treated control group
and all other treatment groups at day 21 (∗∗p = 0 006),
day 28 (∗∗∗p = 0 0016), and day 49 (∗p = 0 023). Speciﬁc
Mann–Whitney post hoc tests revealed statistically signiﬁ-
cant diﬀerences between the AAV-GFP-treated control group
and AAV-CNTFmCherry (p = 0 001 at day 21, p = 0 004 at day
28, and p = 0 003 at day 49), AAV-CNTFmCherry +nonviable
rMPCs (p = 0 018 at day 21, p = 0 036 at day 28, and
p = 0 113 at day 49), and AAV-CNTFmCherry + viable
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Figure 3: Functional hindlimb recovery promoted after AAV-CNTF gene therapy and cellular transplantation as assessed by Ladderwalk:
reduced misstepping over the Ladderwalk apparatus indicates that AAV-CNTFmCherry therapy (red, crosses) promoted signiﬁcant
functional improvement after SCI compared with control AAV-GFP treatment (green). Note that at day 14, the Ladderwalk testing was
carried out prior to injection of either viable (blue) or nonviable (black) cells. Post hoc tests revealed statistically signiﬁcant diﬀerences
between the AAV-GFP-treated control group and AAV-CNTFmCherry + nonviable rMPCs at all time points as well as between the AAV-
GFP-treated control group and AAV-CNTFmCherry + viable rMPCs at all time points except day 56 (∗p = 0 01 – 0 05, ∗∗p = 0 005 – 0 01,
and ∗∗∗p = 0 001 – 0 005). Two-way repeated measures ANOVA was conducted using PRISM (time: p = 0 0001, treatment: p = 0 0016,
and interaction: p = 0 0001). Standard deviation is shown.
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rMPCs (p = 0 021 at day 21, p = 0 008 at day 28, and
p = 0 059 at day 49), respectively.
3.3.3. Ratwalk® Gait Analysis. Ratwalk analysis on animals
showing hindlimb weight support are summarized in
Figure 5, with averages of arbitrary unit values assigned by
the software in silica for each treatment group compared to
preinjury levels (dotted black lines) shown for stance width
(5A), step length (5B), stride length (5C), and step sequence
(5D) at day 56 after injury, by which time any diﬀerences
in gait parameters should be apparent. Stance width is the
average distance between each of the forelimbs (Rf/Lf), each
of the hindlimbs (Rh/Lh), and each of the fore-to-hindlimb
placements (Rf/Lh and Lf/Rh). There was no signiﬁcant
diﬀerence between any treatment group for any variable in
stance width at day 56. Typically, hindlimb stance width
increases slightly very early on after SCI (data not shown)
and although the AAV-GFP-treated control group still
showed a marginally increased average hindlimb stance
width compared to all other treatment groups, there was no
statistical diﬀerence between them or preinjury levels. A
higher average stance width between opposing fore- and
hindlimbs (Rf/Lh and Lf/Rh) was maintained at day 56
post-SCI for all treatment groups compared to preinjury
levels and suggests that all animals assume a longer distance
between each fore- and hindlimbs as a consequence of the
injury irrespective of treatment. The stance width data
suggesting these compensatory fore- and hindlimb changes
in the treatment groups is conﬁrmed by the day 56 post-
SCI analyses for step length (Figure 5(b)) and stride length
(Figure 5(c)), which again showed no statistically signiﬁcant
diﬀerences between treatments. Step length analysis shows
a higher average distance between Rf/Rh, Rf/Lh, Rh/Lf, and
Lf/Lh across all groups compared to preinjury levels with
no statistically signiﬁcant diﬀerences between the groups
(Figure 5(b)). Stride length also shows that generally forelimb
strides are shorter and hindlimb strides are longer on average
compared to preinjury levels (Figure 5(c)), consistent with
the idea that compensatory movements to bring forelimbs
closer and take shorter strides to help “pull” the animal
forward correlates with longer hindlimb strides that adopt a
wider stance (for more stability) and therefore longer
distances. While the AAV-CNTFmCherry + nonviable rMPC
group of animals still showed slightly higher forelimb dis-
tances compared to preinjury levels, there were no statisti-
cally signiﬁcant diﬀerences between treatments.
Step sequence analysis revealed that following SCI, there
was generally a decrease in the amount of patterns of coordi-
nated fore- and hindlimb placements designated as “cruci-
ate,” “alternate,” and “rotary” using the Ratwalk software,
as well as an increase in the amount of unrecognisable (non-
coordinated) fore- and hindlimb placements designated as
“none” (Figure 5(d)). There remained a signiﬁcant decrease
in the amount of cruciate patterns of sequence compared
to preinjury levels, and despite some variation between
treatment groups, there were no statistically signiﬁcant
diﬀerences between treatment groups for both alternate
and rotary patterns of step sequence. The amount of
uncoordinated patterns of step sequence (“none”) was
almost twice as high for all treatment groups at day 56
post-SCI, again with no statistically signiﬁcant diﬀerences
between treatment groups.
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Figure 4: Functional hindlimb recovery promoted after AAV-CNTF gene therapy and cellular transplantation as assessed by open-ﬁeld
locomotion (BBB). Signiﬁcant functional improvements were observed following AAV-CNTFmCherry (red), AAV-CNTFmCherry + nonviable
rMPC (black), and AAV-CNTFmCherry + viable rMPC (blue) treatment compared to AAV-GFP-treated control animals (green) generally
from day 21 after SCI onwards, although statistically signiﬁcant diﬀerences were not maintained at all time points (∗p = 0 01 – 0 05
and ∗∗∗p = 0 001 – 0 005). Standard deviation is shown.
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3.4. Transplantation of Viable rMPCs, but Not Cortical Gene
Therapy, Promotes Tissue Sparing. Cysts developed at the
injury site of all animals in all groups after SCI. The cyst sizes
measured at day 56 after SCI are shown in Figure 6. AAV-
GFP treatment and AAV-CNTFmCherry treatment groups
on average had a 10-11% area of ﬁeld of view occupied by
cysts, respectively. While AAV-CNTFmCherry + nonviable
rMPC-treated animals still showed slightly lower average cyst
sizes of about 8%, there was no statistical diﬀerence between
any of these groups. However, AAV-CNTFmCherry transduc-
tion in the cortex followed by viable rMPC transplantation
into the lesion did result in a statistically signiﬁcant reduction
in average cyst size, to just a 2% area of ﬁeld of view, indicat-
ing that viable rMPCs are able to signiﬁcantly alter the terrain
of the lesion site to aﬀect tissue sparing. Note that two of the
three rats with mCherry-positive axons distal to the injury
site were in the AAV-CNTFmCherry + viable rMPC group.
Donor rMPCs were not labelled with any marker for
identiﬁcation posttransplantation, and there was no evidence
of individual donor rMPCs remaining in spinal cord
sections subjected to immunohistochemistry or toluidine
blue staining (data not shown).
4. Discussion
In this study, we used AAV-CNTFmCherry therapy to trans-
duce neurons, including CSN, in the sensorimotor cortex of
animals with a moderate thoracic (T10) contusion injury,
with the aim of enhancing plasticity and promoting the
regrowth of corticospinal tract axons after SCI. It is widely
acknowledged that combinations of therapies are required
for eﬀective treatment of SCI, thus in some animals AAV-
CNTFmCherry was applied in combination with viable or
nonviable rat mesenchymal precursor cells (rMPCs) grafted
into the spinal lesion site two weeks after SCI to modulate
the local inhibitory environment. As discussed more fully
below, diﬀerent types of AAV vectors have previously been
injected into the cortex in SCI studies, and MPC grafts have
also been tested after SCI, but to our knowledge no trials
have—until now—combined these therapeutic approaches.
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Figure 5: Ratwalk gait analysis at day 56 after SCI. Averages of arbitrary unit values of each treatment group compared to preinjury levels
(dotted black lines) are shown for stance width (a), step length (b), stride length (c), and step sequence (d). Despite no statistically
signiﬁcant diﬀerences between any treatment group for any variable, compensatory changes such as a marked reduction in the stance
width (a) of the forelimbs (Rf/Lf) between opposing fore- and hindlimbs (Rf/Lh and Lf/Rh) in all groups compared to preinjury levels
were supported by data for step length (b) and stride length (c). A general decrease in the amount of patterns of coordinated fore- and
hindlimb placement (“cruciate,” “alternate,” and “rotary” as indicated in (d)) and an increase in the amount of noncoordinated fore- and
hindlimb placement (“none”) was observed. Standard deviation is shown.
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AAV-CNTFmCherry therapy alone or in combination with
either viable or nonviable rMPC transplantation provided a
sustained improvement in functional outcome over AAV-
GFP alone as measured by Ladderwalk. Note that with this
behavioural test, while control and CNTF treatments
diﬀered, there was no signiﬁcant diﬀerence between the
diﬀerent AAV-CNTFmCherry groups (no cells, viable cells,
and nonviable cells), thus it seems that the presence of
cortical CNTF was suﬃcient to yield an improvement in
the stepping function. AAV-CNTFmCherry therapy alone
and in combination with rMPC transplantation also yielded
sustained improvements as assessed by open-ﬁeld locomo-
tion (BBB). Ratwalk gait analyses revealed subtle compen-
satory mechanisms for limb placement after injury, but it
is likely that even the moderate injury used here was too
severe to reveal signiﬁcant statistical diﬀerences. The aver-
age cyst size was signiﬁcantly reduced only in the AAV-
CNTFmCherry + viable rMPC group.
In addition to many degenerative proﬁles, the sprouting
of apparently intact axons was evident in the CST immedi-
ately rostral to the injury site. Compared to AAV-GFP con-
trols, considerably more BDA or mCherry-labelled axons
with complex proﬁles were located just rostral to the cysts
in the AAV-CNTFmCherry-injected rats containing CNTF-
transduced cortical neurons. Not only was the density of
these axons higher, but the area of the spinal cord containing
them extended further rostrally into uninjured segments.
Furthermore, only in AAV-CNTFmCherry-transduced treat-
ment groups were BDA and mCherry-immunoreactive
axons seen to project alongside, and sometimes several
millimeters beyond, the rostral border of the lesion-induced
cysts. It is important to emphasize that, compared to oriented
and organized ﬁbers in the CST far rostral to the injury site,
axons were more irregularly organized immediately in front
of, as well as caudal to, cysts, strongly suggestive of local
sprouting and regenerative responses.
In three of the eleven animals that received cortical AAV-
CNTFmCherry injections, axons were seen caudal to all cysts,
located up to 3-4mm beyond the rostral edge of the injury
site. These axons were seen in two non-rMPC grafted ani-
mals as well as in a rat that also received an rMPC transplant.
We did not detect such axons in AAV-GFP-injected animals,
again supporting the suggestion that CNTF has the potential
to enhance axon regeneration in the spinal cord by transduc-
ing appropriate neuronal populations in the sensorimotor
cortex. In other CNS systems, vector-mediated delivery of
CNTF to parent cell bodies combined with the transplanta-
tion of an appropriate bridging substrate (peripheral nerve),
promotes the long-distance regeneration of injured axons
[7–10], with at least some functional outcomes [11]. Note
in particular that the survival eﬀects of CNTF have been
demonstrated on numerous neuron populations [14–16],
including increasing the viability of corticospinal neurons
in the sensorimotor cortex after intracortical axotomy
[6]. Because AAV-CNTF delivery is only to the cortex,
the primary site of trophic action is at the cell bodies,
and transport and release of CNTF at axon tips likely
occurs at a low level (we have conﬁrmed this previously,
data not shown). Based on previous studies in the visual
system, we propose that the mechanisms of protection
and promotion of plasticity and regenerative capacity are
mediated and ampliﬁed both by direct infection of CSN
themselves but also due to bystander release of CNTF by
adjacent nonprojecting cortical cells [8, 39]. Many of the
biological actions of CNTF are signalled via STAT3, and
it is therefore important to note that vector-mediated
delivery of a hyperactivated STAT3 enhances process
outgrowth in cultured cortical neurons [40], and in vivo
overexpression of STAT3 enhances CSN plasticity in mice
after SCI [41].
Delivery of AAV vectors to the cortex has been reported
by a number of groups, some to test the optimal serotype for
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Figure 6: Tissue sparing promoted by combined cortical AAV-CNTFmCherry therapy and local transplantation of viable rMPCs. AAV-GFP
control treatment and AAV-CNTFmCherry treatment groups revealed similar average areas of cyst formation in spinal cord sections stained by
toluidine blue, and although AAV-CNTFmCherry + nonviable rMPC treatment resulted in slightly lower average cyst sizes, only
AAV-CNTFmCherry + viable rMPC treatment into the lesion resulted in a statistically signiﬁcant reduction in average cyst size. ∗p = 0 01 – 0 05.
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transduction of cortical neurons, including CSN [42, 43],
others to deliver factors designed to enhance CST repair after
SCI [44–49]. Such studies are nonetheless much less frequent
than those involving the delivery of vectors and/or growth
factors to the spinal cord injury site itself [2, 50]. In some
initial studies, we tested the eﬀect of the cortical injection
of AAV1 expressing insulin-like growth factor 1 (IGF-1) on
CST plasticity after SCI, but although we saw some additional
sprouting rostral to the injury, this was less than that seen
after the cortical delivery of AAV-CNTF vectors, and we
saw no signiﬁcant changes in functional recovery (unpub-
lished data). Interestingly then, postlesion AAV-assisted
coexpression of IGF1 and osteopontin in cortical neurons
resulted in robust CST regrowth and the recovery of
CST-dependent behavioural outcomes after SCI [50], again
indicative of the therapeutic power of combined therapies.
The long-term transduction of murine cortical neurons
using an AAV vector to suppress or conditionally delete
expression of phosphatase and tensin homolog (PTEN), the
main suppressor of the PI3K-Akt survival and growth
pathway, leads to the greater regenerative growth of CST
axons and some functional improvements [45]. However
the resultant long-term upregulation of protein kinases such
as mTOR, a key regulator of protein translation in neurons,
leads to some aberrant growth [48] and progressive changes
in the growth of cells, their dendrites, and their axons [46].
This is not dissimilar to the eﬀect of long-term (up to
one year) AAV-mediated expression of CNTF on retinal
ganglion cells, where there are not only changes in the
dendritic morphology of transduced and neighboring non-
transduced cells [51], but there is also altered expression
of endogenous retinal genes [52]. Whether such eﬀects are
also seen in cortical neurons transduced with AAV-CNTF
is yet to be determined, but this is an important topic for
future studies.
MPCs from the bone marrow stroma have the potential
to diﬀerentiate into cells with many of the phenotypic
characteristics of neural tissue [53–55], migrate and inte-
grate into CNS tissues, and express markers typical of
mature neurons and astrocytes [56]. MPCs have been
successfully transplanted into the spinal cord and shown
to (a) promote regeneration of lesioned axons into the
graft, (b) diﬀerentiate into neurons, (c) remyelinate dam-
aged myelin sheaths around CNS axons, and (d) improve
functional outcomes after SCI (for extensive reviews, see
[57, 58]). Our own work using puriﬁed (Stro-1+) human
MPCs from the bone marrow stroma of SCI patients
dramatically improved anatomical (characterized by smaller
cyst sizes, as well as lower amounts of degenerative tissue)
and functional recovery after both acute and subacute/
chronic SCI in nude rat (T-cell immunodeﬁcient) hosts after
contusion SCI [24, 25]. Rat MPCs can be prepared to an
essentially pure, minor subpopulation of adult cells [59–61]
signiﬁcantly lessening any potential variation in functional
and morphological outcomes, often encountered in the
literature when using diﬀerent hMPC donor cells in trans-
plantation experiments.
rMPC transplantation at day 14 post-SCI presumably
avoids the cytotoxicity of the acute injury and presumably
allows suﬃcient time for targeted expression of CNTF to be
switched on in transduced cortical cells [2, 4, 28]. Generally,
SCI studies show signiﬁcant results attributable to transplan-
tation within a few weeks of injection [24, 25, 57, 62, 63];
however, in the present study the impact of rMPCs grafted
into the injury site was evident in reducing postlesion cavity
dimensions, but eﬀects were absent or inconsistent in the
behavioural studies involving AAV-CNTFmCherry-injected
animals. It should be noted that a caveat of this study is that
behavioural tests were continued after BDA was injected
which could potentially obscure or increase treatment eﬀects
due to the injection-associated injury and surgery, although
we did not observe any apparent reduction in functional
outcomes between BDA injection and the ﬁnal time points
analysed. There did not appear to be greater macrophage/
microglial reactivity associated with AAV transduction
(either AAV-GFP-treated control or AAV-CNTFmCherry
treatments) beyond that typically observed in our other SCI
studies [24, 25]. MPCs do produce some CNTF [64] but
our experience is that, while MPCs alter the local environ-
ment to enhance axonal regrowth, few survive in the long
term [24, 25]. Only viable rMPC grafts promoted statistically
signiﬁcant tissue sparing, yet nonviable rMPC transplanta-
tion had similar eﬀects as viable rMPC transplantation in
functional outcomes (as shown in our Ladderwalk and
open-ﬁeld assays). The use of (freeze-thawed) nonviable cells
as appropriate controls for cell transplantation studies in SCI
is by no means common. There is evidence to suggest that
even ﬁbroblasts can contribute to functional and/or morpho-
logical improvements in animal models of SCI compared to
speciﬁc stem/precursor cell types [57, 63]. Indeed some
studies have reported functional improvements without
associated (and expected?) structural improvements, and
vice versa [57, 65]. A possible scenario is that MPCs (which
are known to have immunosuppressive properties [66])
may act as immune “decoys” that modulate the host immune
response (e.g., [67]) and this property may still be eﬀective
even if the cells themselves are not viable. This could
potentially allow the “normal” host repair mechanism to be
more eﬀective and be reﬂected in either functional and/or
morphological outcomes.
4.1. Impact and Future Direction. The combination of AAV-
targeted expression of CNTF, with or without the use of stem
cell graft technology, represents a novel strategy to assess the
eﬀect of vector-mediated production of growth factors on
plasticity and regeneration after SCI. A major aim of these
experiments was to assess the capability of cortical gene
therapy to promote potential plasticity and regrowth/
regeneration of CST axons. The present behavioural and
morphological data after thoracic contusion injury show
the promise of using cortical AAV-CNTF gene therapy
to promote repair after SCI. In future studies, we will test
this approach in a model of cervical CST hemitransection,
focusing on the importance of this tract in rodent forelimb
function. The data presented here aid in the advancement of
technologies related to the development of more eﬀective
gene therapy and begin to provide a platform for exploring
the possibility of preclinical studies aimed at using gene
12 Neural Plasticity
therapy to modify cortical neurons as part of an SCI
repair strategy.
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